Left Menu
Development News Edition

Germany plays catch-up in bid to monitor coronavirus mutations

Germany wants to jump-start gene sequencing efforts to closely track coronavirus mutations and catch up with European nations such as Britain and Denmark which have taken the lead on decoding viral genomes. More contagious coronavirus variants are believed by scientists to have fuelled a surge in global coronavirus cases which have now passed 90 million, and nations are racing to procure vaccines and tighten lockdown measures.

Reuters | Updated: 14-01-2021 18:00 IST | Created: 14-01-2021 17:46 IST
Germany plays catch-up in bid to monitor coronavirus mutations
Representative Picture. Image Credit: Twitter(@WHO)

Germany wants to jump-start gene sequencing efforts to closely track coronavirus mutations and catch up with European nations such as Britain and Denmark which have taken the lead on decoding viral genomes.

More contagious coronavirus variants are believed by scientists to have fuelled a surge in global coronavirus cases which have now passed 90 million, and nations are racing to procure vaccines and tighten lockdown measures. A draft government order released for discussion by the German Health Ministry this week would require 5% of all samples from positive coronavirus tests to be sent to specialised laboratories for a complete genetic read-out.

That compares with a rate of about 5%-10% of viral samples being sequenced in Britain, according to the Robert Koch Institute (RKI), Germany's infectious disease agency. Denmark, another pioneer in the field, has said it has the capacity to analyse up to 10,000 positive samples per week.

Around 13% of all positive samples have so far been sequenced, a process that determines the order of chemical building blocks in a DNA molecule, allowing researchers to identify changes in genes and ways to respond. Denmark hopes to increase its sequencing capacity further.

"There is nothing to prevent us from analysing all samples in Denmark - realistically within three weeks," Mads Albertsen, biotechnology professor at Aalborg University and the head of Denmark's largest genome sequencing facility, told Reuters. The RKI estimates that 200 to 250 cases were sequenced in December in Germany, which is home to COVID-19 vaccine developers BioNTech and CureVac.

Britain, which has made mass gene sequencing a national priority, is sequencing several thousand cases each day. It started tracking virus mutations broadly across its population early during the pandemic, led by the COVID-19 Genomics UK (COG-UK) consortium with partners including the National Health Service and the Wellcome Sanger Institute.

LESS VISIBILITY In its attempt to catch up, Germany would reimburse laboratories 200 euros ($243) per viral genome sequenced under the draft order, while the government has earmarked 200 million euros for the effort.

Marco Binder, a virologist at the German Cancer Research Center (DKFZ) in Heidelberg, which runs the country's largest human genome sequencing facility, said the German science community traditionally had other priorities. Sporadic coronavirus sequencing had previously been enough to stay on top of its relatively slow genomic shifts, but the emergence of faster-spreading variants posed a new imperative.

"We probably underestimated that," he said. "It is indeed important and worth the effort to be able to track this fast and well, also on a local level." "We in Germany clearly have less visibility than is the case, say, in the UK or Denmark," he said.

The association of German diagnostic labs, ALM, said the industry had the capacity to meet the government's call. "The 5% strike rate is quite doable," said ALM board member Evangelos Kotsopoulos. "The capacity is there, the equipment is there, the people are there."

The ALM said some work was needed to ensure that German laboratories pursued a common sequencing method, praising the open collaboration of Britain's genomic sequencing effort. Scientists also see a need for a coordinated European approach. "This is not the last variant that we will encounter," Andreas Bergthaler, of the Research Center for Molecular Medicine at the Austrian Academy of Sciences, said of the new strain in Britain.

"We should keep our eyes open and build these systems and technologies much more systematically."

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

China: A savior for emerging markets or a poison pill?

... ...

Future of Urban Planning: Artificial Intelligence guiding the way

Advances in emerging technologies like Artificial Intelligence and Machine Learning can help us understand our cities better and derive useful insights from real-time data collected through automated models....

Videos

Latest News

Chinese media criticise Pfizer COVID-19 vaccine, tout local shots

Chinese state media outlets have run a series of articles criticising Western COVID-19 vaccines in the past week, including Pfizers, while touting China-made vaccines as safer and more accessible.The reports have come as Chinas vaccines, wh...

Return of Virat Kohli: No threat to captaincy but he will be among "equals" in that dressing room

First things first. There is no imminent threat to Virat Kohlis captaincy in any format and neither is BCCI even remotely thinking on those lines. But thats the news part of the story. When it comes to views, there are many -- some are quit...

Morgan Stanley profit surges on trading strength

Morgan Stanley posted an about 57 rise in fourth-quarter profit on Wednesday, as the Wall Street banks trading business benefited from coronavirus-induced volatility in financial markets.Net income applicable to common shareholders rose to ...

EU says Alitalia brand must go in airline's revamp -L'Espresso

Italy would have to drop the 75-year-old Alitalia brand if it wants the European Commission to approve plans to relaunch the airline, according to a letter published by LEspresso magazine. Loss-making Alitalia has endured 11 years of turbul...

Give Feedback